The role of a ginseng saponin metabolite as a DNA methyltransferase inhibitor in colorectal cancer cells

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 228-236

  Kang, Kyoung Ah ^a   Kim, Hee Sun ^b   Kim, Dong Hyun ^c   Hyun, Jin Won ^a  

^a Jeju National University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

Colorectal cancer; DNA methyltransferase; Epigenetic alteration; Ginseng saponin metabolite; Tumor suppressor gene

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE INHIBITOR; GINSENG SAPONIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SMAD4 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX3;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL NUCLEUS; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA ISOLATION; WESTERN BLOTTING;

COLORECTAL NEOPLASMS; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GINSENOSIDES; HT29 CELLS; HUMANS; PANAX; PROMOTER REGIONS, GENETIC; SAPONINS; SMAD4 PROTEIN;

EID: 84879618317     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1931     Document Type: Article

References (57)

1. Kudo S, Lambert R, Allen JI, et al: Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc 68: S3-S47, 2008.
2. Smith JJ, Deane NG, Dhawan P and Beauchamp RD: Regulation of metastasis in colorectal adenocarcinoma: A collision between development and tumor biology. Surgery 144: 353-366, 2008.
3. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 1996. (Pubitemid 26358996)
4. Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135: 1079-1099, 2008.
5. Wong JJ, Hawkins NJ and Ward RL: Colorectal cancer: a model for epigenetic tumorigenesis. Gut 56: 140-148, 2007. (Pubitemid 46044900)
6. Matos E and Brandani A: Review on meat consumption and cancer in South America. Mutat Res 506-507: 243-249, 2002. (Pubitemid 35286559)
7. Nkondjock A and Ghadirian P: Associated nutritional risk of breast and colon cancers: a population-based case control study in Montreal, Canada. Cancer Lett 223: 85-91, 2005. (Pubitemid 40693712)
8. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
9. Grady WM: Genomic instability and colon cancer. Cancer Metastasis Rev 23: 11-27, 2004.
10. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003. (Pubitemid 37448928)
11. Levanon D, Brenner O, Negreanu V, et al: Spatial and temporal expression pattern of Runx3 (Aml2) and Runx1 (Aml1) indicates non-redundant functions during mouse embryogenesis. Mech Dev 109: 413-417, 2001. (Pubitemid 33112059)
12. Woolf E, Xiao C, Fainaru O, et al: Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA 100: 7731-7736, 2003. (Pubitemid 36760038)
13. Li QL, Kim HR, Kim WJ, et al: Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun 314: 223-228, 2004.
14. Chuang LS and Ito Y: RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 29: 2605-2615, 2010.
15. Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V and Ingvarsson S: Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br J Cancer 79: 1468-1474, 1999. (Pubitemid 29116806)
16. Tanaka K, Yanoshita R, Konishi M, et al: Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 8: 2253-2258, 1993. (Pubitemid 23226960)
17. Li QL, Ito K, Sakakura C, et al: Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-124, 2002. (Pubitemid 34327521)
18. Goel A, Arnold CN, Tassone P, et al: Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer 112: 754-759, 2004. (Pubitemid 39435259)
19. Jair KW, Bachman KE, Suzuki H, et al: De novo CpG island methylation in human cancer cells. Cancer Res 66: 682-692, 2006. (Pubitemid 43165930)
20. Rhee I, Bachman KE, Park BH, et al: DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416: 552-556, 2002. (Pubitemid 34288859)
21. Lu R, Wang X, Chen ZF, Sun DF, Tian XQ and Fang JY: Inhibition of the extracellular signal-regulated kinase/mitogenactivated protein kinase pathway decreases DNA methylation in colon cancer cells. J Biol Chem 282: 12249-12259, 2007. (Pubitemid 47100721)
22. Santi DV, Norment A and Garrett CE: Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81: 6993-6997, 1984.
23. Gabbara S and Bhagwat AS: The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307: 87-92, 1995.
24. Mack GS: Epigenetic cancer therapy makes headway. J Natl Cancer Inst 98: 1443-1444, 2006.
25. Beisler JA: Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 21: 204-208, 1978.
26. Constantinides PG, Jones PA and Gevers W: Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 267: 364-366, 1977. (Pubitemid 8119790)
27. Lyko F and Brown R: DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97: 1498-1506, 2005. (Pubitemid 41631949)
28. Gaudet F, Hodgson JG, Eden A, et al: Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492, 2003. (Pubitemid 36444330)
29. Howard G, Eiges R, Gaudet F, Jaenisch R and Eden A: Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27: 404-408, 2008.
30. Deng T and Zhang Y: 5-Aza-2'-deoxycytidine reactivates expression of RUNX3 by deletion of DNA methyltransferases leading to caspase independent apoptosis in colorectal cancer Lovo cells. Biomed Pharmacother 63: 492-500, 2009.
31. Hong SY, Cho JY and Seo DW: Ginsenoside Rp1 inhibits proliferation and migration of human lung cancer cells. Biomol Ther 19: 411-418, 2011.
32. Park JW, Lee JC, Ann S, et al: A fermented ginseng extract, BST204, inhibits proliferation and motility of human colon cancer cells. Biomol Ther 19: 211-217, 2011.
33. Seo EY and Kim WK: Red ginseng extract reduced metastasis of colon cancer cells in vitro and in vivo. J Ginseng Res 35: 315-324, 2011.
34. Akao T, Kanaoka M and Kobashi K: Appearance of compound K, a major metabolite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration-measurement of compound K by enzyme immunoassay. Biol Pharm Bull 21: 245-249, 1998. (Pubitemid 28166911)
35. Hasegawa H, Sung JH and Huh JH: Ginseng intestinal bacterial metabolite IH901 as a new anti-metastatic agent. Arch Pharm Res 20: 539-544, 1997. (Pubitemid 127697216)
36. Quan LH, Cheng LQ, Kim HB, et al: Bioconversion of ginsenoside Rd into compound K by Lactobacillus pentosus DC101 isolated from Kimchi. J Gins Res 34: 288-295, 2010.
37. Kang KA, Kim YW, Kim SU, et al: G1 phase arrest of the cell cycle by a ginseng metabolite, compound K, in U937 human monocytic leukamia cells. Arch Pharm Res 28: 685-690, 2005.
38. Kang KA, Lim HK, Kim SU, et al: Induction of apoptosis by ginseng saponin metabolite in U937 human monocytic leukemia cells. J Food Biochem 29: 27-40, 2005. (Pubitemid 40737567)
39. Chae S, Kang KA, Chang WY, et al: Effect of compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo. J Agric Food Chem 57: 5777-5782, 2009.
40. Kim AD, Kang KA, Zhang R, et al: Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol 30: 134-140, 2010.
41. Ito K, Lim AC, Salto-Tellez M, et al: RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237, 2008.
42. Ku JL, Kang SB, Shin YK, et al: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23: 6736-6742, 2004.
43. Yano T, Ito K, Fukamachi H, et al: The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 26: 4474-4488, 2006. (Pubitemid 43877568)
44. Tong DD, Jiang Y, Li M, et al: RUNX3 inhibits cell proliferation and induces apoptosis by TGF-beta-dependent and -independent mechanisms in human colon carcinoma cells. Pathobiology 76: 163-169, 2009.
45. Kodach LL, Jacobs RJ, Heijmans J, et al: The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31: 1567-1575, 2010.
46. Lee IK, Kang KA, Lim CM, et al: Compound K, a metabolite of ginseng saponin, induces mitochondria-dependent and caspase-dependent apoptosis via the generation of reactive oxygen species in human colon cancer cells. Int J Mol Sci 11: 4916-4931, 2010.
47. Subramaniam MM, Chan JY, Soong R, et al: RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 113: 113-121, 2009.
48. Ito K, Liu Q, Salto-Tellez M, et al: RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res 65: 7743-7750, 2005. (Pubitemid 41297249)
49. Mani S and Herceg Z: DNA demethylating agents and epigenetic therapy of cancer. Adv Genet 70: 327-240, 2010.
50. Howell PM, Liu Z and Khong HT: Demethylating agents in the treatment of cancer. Pharmaceuticals 3: 2022-2044, 2010.
51. Fang MZ, Wang Y, Ai N, et al: Tea polyphenol (-)-epigallocatechin- 3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63: 7563-7570, 2003. (Pubitemid 37466673)
52. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK and Yang CS: Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 11: 7033-7041, 2005. (Pubitemid 41428763)
53. Fini L, Selgrad M, Fogliano V, et al: Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells. J Nutr 137: 2622-2628, 2007. (Pubitemid 350255288)
54. Kishikawa S, Murata T, Ugai H, Yamazaki T and Yokoyama KK: Control elements of Dnmt1 gene are regulated in cell-cycle dependent manner. Nucleic Acids Res (Suppl) 3: 307-308, 2003.
55. Torquati A, O'rear L, Longobardi L, et al: RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery 136: 310-316, 2004.
56. Yamamura Y, Lee WL, Inoue K, Ida H and Ito Y: RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281: 5267-5276, 2006. (Pubitemid 43847791)
57. Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA 99: 8048-8053, 2002. (Pubitemid 34651003) and Welfare